At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 7 enrolled
Drug / intervention
Perampaneldrug
Likely dose
Perampanel 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
In Brief
A Phase 3 clinical trial evaluating Perampanel for Epilepsy. Completed, enrolled 7 participants across 8 sites.
Detailed Summary
To evaluate the safety and tolerability of perampanel given as an adjunctive therapy in participants with epilepsy. This study will be continued until perampanel is commercially available.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartMay 2015
Primary CompletionSep 2016
Study CompletionNov 2016
TodayJul 2026
First PostedApr 28, 2015
Enrollment StartMay 12, 2015
Primary CompletionSep 21, 2016
Study CompletionNov 9, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.2 years ago
Interventions
Perampaneldrug
Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.